CAR T-Cell Therapy Advances in Lymphoma: Implications for Managed Care

Program Description

The use of chimeric antigen receptor (CAR)-modified T-cell therapies for hematologic malignancies is rapidly expanding. Although CD19-directed CAR T-cell therapies have shown great promise in improving patient outcomes and have been incorporated into guidelines for the treatment of relapsed and refractory lymphoma, use remains limited by the potential to cause life-threatening toxicities as well as cost. With emerging data on indications for therapy and financial regulations for CAR T-cell therapy, managed care professionals are challenged to make CAR T-cell therapy more accessible for patients. This article will explore FDA-approved indications of CD19-directed CAR T-cell therapies, focusing on data for second-line therapy in large B-cell lymphoma and the management of CAR T-cell‒related toxicities. Managed care professionals and pharmacists involved in the care of patients with lymphoma will gain insight to expand their roles in the management of serious toxicities as well as the costs associated with CAR T-cell treatment to ensure provision of cost-effective, patient-centered care.

Target audience: Managed care and oncology pharmacists

Type of activity: Application
Release date: October 28, 2022
Expiration date: March 31, 2024

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explore recent evidence supporting the use of chimeric antigen receptor (CAR)-modified T-cell therapies in lymphoma
• Interpret the guideline recommendations for implementation of CAR T-cell therapy in treatment pathways and management of associated adverse effects
• Identify the value and access considerations for CAR T-cell therapy indicated for the treatment of lymphomas